Home LiteratureArticle Details
PMID: 17166272 Published · epublish English Journal Article

In situ analysis of FOXP3+ regulatory T cells in human colorectal cancer.

Journal of translational medicine ·Vol. 4 ·2006-12-13 ·Pages 52

Loddenkemper C, Schernus M, Noutsias M, Stein H, Thiel E, Nagorsen D

Abstract

The immune system spontaneously responds to tumor-associated antigens in peripheral blood of colorectal cancer (CRC) patients. Regulatory T cells (Treg) are suspected of influencing the interaction between the tumor and immune system and thus the course of malignant diseases. However, the function of Tregs in the development of T cell responses and on the clinical course of CRC is not clear. We analyzed Treg infiltration (FOXP3 staining) in situ in 40 CRC patients and investigated whether there is a correlation to disease stage, systemic T cell response, and survival. Treg infiltration was significantly higher in CRC than in healthy colon. Stromal Treg infiltration was significantly higher than epithelial infiltration in CRC. Furthermore, Treg infiltration in the tumor was significantly higher in limited disease than in metastatic CRC. The average Treg infiltration rate in the tumor was non-significantly higher in patients without systemic TAA-specific T cell response. Survival did not differ between patients with high Treg infiltration and those with low Treg infiltration. In conclusion, a direct link between Treg infiltration in the tumor and the development of a systemic T cell response in CRC cannot be proven. However, local Treg infiltration was significantly higher in limited disease, in which a systemic TAA-directed T cell responses is less frequently observed.

Authors & Affiliations
6 authors, click to expand affiliations / ORCID
Loddenkemper Christoph
Department of Pathology, Charité -Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany. christoph.loddenkemper@charite.de
Schernus Martin
Noutsias Michel
Stein Harald
Thiel Eckhard
Nagorsen Dirk
References (47)
47 references, click to expand
  1. Effector memory T cells, early metastasis, and survival in colorectal cancer.
    N Engl J Med. 2005 Dec 22;353(25):2654-66 PMID: 16371631
  2. The expression of the regulatory T cell-specific forkhead box transcription factor FoxP3 is associated with poor prognosis in ovarian cancer.
    Clin Cancer Res. 2005 Dec 1;11(23):8326-31 PMID: 16322292
  3. Analysis of FOXP3 protein expression in human CD4(+)CD25(+) regulatory T cells at the single-cell level.
    Eur J Immunol. 2006 Jan;36(1):245; author reply 246 PMID: 16380960
  4. CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer.
    Cancer Res. 1998 Aug 15;58(16):3491-4 PMID: 9721846
  5. CD4(+)CD25(+) regulatory lymphocytes require interleukin 10 to interrupt colon carcinogenesis in mice.
    Cancer Res. 2003 Sep 15;63(18):6042-50 PMID: 14522933
  6. CD4(+)CD25high regulatory T cells increase with tumor stage in patients with gastric and esophageal cancers.
    Cancer Immunol Immunother. 2006 Sep;55(9):1064-71 PMID: 16328385
  7. CD4+CD25+ regulatory T cells in the peripheral blood of patients with breast cancer and non-small cell lung cancer.
    Oncol Rep. 2005 Nov;14(5):1269-73 PMID: 16211295
  8. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells.
    Nat Immunol. 2003 Apr;4(4):330-6 PMID: 12612578
  9. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors.
    J Exp Med. 2005 Mar 7;201(5):779-91 PMID: 15753211
  10. Increased populations of regulatory T cells in peripheral blood and tumor-infiltrating lymphocytes in patients with gastric and esophageal cancers.
    Clin Cancer Res. 2003 Oct 1;9(12):4404-8 PMID: 14555512
  11. CD4+ CD25+ regulatory T cells control the induction of antigen-specific CD4+ helper T cell responses in cancer patients.
    Blood. 2005 Aug 1;106(3):1008-11 PMID: 15840697
  12. Outcome in Hodgkin's lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells.
    Clin Cancer Res. 2005 Feb 15;11(4):1467-73 PMID: 15746048
  13. Natural T cell immunity against cancer.
    Clin Cancer Res. 2003 Oct 1;9(12):4296-303 PMID: 14555498
  14. Mucosal FOXP3+ regulatory T cells are numerically deficient in acute and chronic GvHD.
    Blood. 2006 Feb 15;107(4):1717-23 PMID: 16278306
  15. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival.
    Nat Med. 2004 Sep;10(9):942-9 PMID: 15322536
  16. Natural T-cell response against MHC class I epitopes of epithelial cell adhesion molecule, her-2/neu, and carcinoembryonic antigen in patients with colorectal cancer.
    Cancer Res. 2000 Sep 1;60(17):4850-4 PMID: 10987297
  17. Prognostic value of the CD4+/CD8+ ratio of tumour infiltrating lymphocytes in colorectal cancer and HLA-DR expression on tumour cells.
    Cancer Immunol Immunother. 2003 Jul;52(7):423-8 PMID: 12695859
  18. Peripheral and intestinal regulatory CD4+ CD25(high) T cells in inflammatory bowel disease.
    Gastroenterology. 2005 Jun;128(7):1868-78 PMID: 15940622
  19. Foxp3 expressing CD4+CD25(high) regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells.
    J Immunol. 2004 Jul 15;173(2):1444-53 PMID: 15240741
  20. Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites.
    Cancer Immunol Immunother. 2005 Nov;54(11):1072-81 PMID: 15959774
  21. An essential role for Scurfin in CD4+CD25+ T regulatory cells.
    Nat Immunol. 2003 Apr;4(4):337-42 PMID: 12612581
  22. Prognostic significance of CD8+ T cell and macrophage peritumoral infiltration in colorectal cancer.
    Oncol Rep. 2003 Mar-Apr;10(2):309-13 PMID: 12579264
  23. Inflammation, a key event in cancer development.
    Mol Cancer Res. 2006 Apr;4(4):221-33 PMID: 16603636
  24. Increased populations of regulatory T cells in peripheral blood of patients with hepatocellular carcinoma.
    Cancer Res. 2005 Mar 15;65(6):2457-64 PMID: 15781662
  25. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.
    J Immunol. 2005 Mar 1;174(5):2591-601 PMID: 15728465
  26. Different occurrence of CD8+, CD45R0+, and CD68+ immune cells in regional lymph node metastases from colorectal cancer as potential prognostic predictors.
    Int J Colorectal Dis. 2002 Jan;17(1):25-9 PMID: 12018450
  27. Induction of tumor immunity by removing CD25+CD4+ T cells: a common basis between tumor immunity and autoimmunity.
    J Immunol. 1999 Nov 15;163(10):5211-8 PMID: 10553041
  28. T cell responses against tumor associated antigens and prognosis in colorectal cancer patients.
    J Transl Med. 2005 Jan 19;3(1):3 PMID: 15659244
  29. Regulatory T cells, tumour immunity and immunotherapy.
    Nat Rev Immunol. 2006 Apr;6(4):295-307 PMID: 16557261
  30. Control of regulatory T cell development by the transcription factor Foxp3.
    Science. 2003 Feb 14;299(5609):1057-61 PMID: 12522256
  31. High numbers of tumor-infiltrating FOXP3-positive regulatory T cells are associated with improved overall survival in follicular lymphoma.
    Blood. 2006 Nov 1;108(9):2957-64 PMID: 16825494
  32. Naturally arising CD25+CD4+ regulatory T cells in tumor immunity.
    Curr Top Microbiol Immunol. 2005;293:287-302 PMID: 15981485
  33. Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells.
    J Exp Med. 2004 Sep 20;200(6):771-82 PMID: 15381730
  34. Intraepithelial CD8+ T-cell-count becomes a prognostic factor after a longer follow-up period in human colorectal carcinoma: possible association with suppression of micrometastasis.
    Br J Cancer. 2004 Nov 1;91(9):1711-7 PMID: 15494715
  35. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative.
    Eur J Immunol. 2004 Feb;34(2):336-44 PMID: 14768038
  36. Prognostic value of tumour-infiltrating lymphocytes (TILs) in colorectal cancer.
    J Pathol. 1997 Jul;182(3):318-24 PMID: 9349235
  37. The role of tumor stroma in the interaction between tumor and immune system.
    Curr Opin Immunol. 2005 Apr;17(2):180-6 PMID: 15766679
  38. The role of immune cells in the tumor microenvironment.
    Cancer Treat Res. 2006;130:103-24 PMID: 16610705
  39. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor alpha) monoclonal antibody.
    Cancer Res. 1999 Jul 1;59(13):3128-33 PMID: 10397255
  40. CD4+CD25+ regulatory T cells in patients with gastrointestinal malignancies: possible involvement of regulatory T cells in disease progression.
    Cancer. 2003 Sep 1;98(5):1089-99 PMID: 12942579
  41. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer.
    Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43 PMID: 16344461
  42. Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes.
    Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14639-45 PMID: 15381769
  43. Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells.
    J Exp Med. 2005 Oct 3;202(7):885-91 PMID: 16186187
  44. Recent developments in therapeutic cancer vaccines.
    Nat Clin Pract Oncol. 2005 Feb;2(2):108-13 PMID: 16264883
  45. Increase of regulatory T cells in the peripheral blood of cancer patients.
    Clin Cancer Res. 2003 Feb;9(2):606-12 PMID: 12576425
  46. Clinical and immunologic responses to active specific cancer vaccines in human colorectal cancer.
    Clin Cancer Res. 2006 May 15;12(10):3064-9 PMID: 16707603
  47. Differences in T-cell immunity toward tumor-associated antigens in colorectal cancer and breast cancer patients.
    Int J Cancer. 2003 Jun 10;105(2):221-5 PMID: 12673683
Article Info
Journal
Journal of translational medicine
Abbr.
J Transl Med
ISSN
1479-5876
DOI
10.1186/1479-5876-4-52
Email
christoph.loddenkemper@charite.de
Published
2006-12-13
Epub
2006-00-13
Pages
52
Language
English
Region
England
NLM ID
101190741
PMCID
PMC1764431
External Links
PubMed source DOI: 10.1186/1479-5876-4-52 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2